Q2 2025 Pulse Biosciences Inc Earnings Call Transcript
Key Points
- Pulse Biosciences Inc (PLSE) has developed a next-generation energy modality, nanosecond pulse field ablation technology (NSPFA), which offers a fundamentally differentiated mechanism of action with reduced risk of thermal damage.
- The company has expanded pilot utilization of its percutaneous electrode for soft tissue ablation, initially targeting benign thyroid disease, demonstrating significant nodule size reduction and symptom relief.
- Pulse Biosciences Inc (PLSE) has submitted two IDEs for regulatory review, advancing towards its regulatory goals with the NSPFA 360 catheter for atrial fibrillation and the cardiac surgical clamp.
- The company is generating positive clinical results in Europe with its cardiac devices, increasing awareness and support among clinicians.
- Pulse Biosciences Inc (PLSE) is making solid progress with its catheter IDE and is engaged in interactive review with the FDA, remaining on track to commence an IDE study soon.
- Total GAAP costs and expenses increased significantly by $8.5 million to $20.3 million compared to the prior year period, driven by administrative expenses and stock-based compensation.
- The company reported a GAAP net loss of $19.2 million in the second quarter of 2025, compared to $11.4 million in the prior year period.
- Cash used in operating activities increased to $12.8 million in the second quarter of 2025, compared to $8.4 million in the prior year period.
- Pulse Biosciences Inc (PLSE) expects quarterly cash use to increase further as it invests in commercial infrastructure and IDE clinical studies.
- Revenue recognition from the percutaneous electrode is expected to vary based on individual contracts, which may lead to deferred revenue depending on specific agreements.
Hello and welcome to the Pulse Biosciences 2nd quarter 2025 earnings conference call. Please note that this call is being recorded.
I would now like to hand the call over to Trip Taylor.
Sir, please go ahead.
Thank you, operator. Before we begin, I would like to inform you that comments and responses to your questions during today's call reflect management's views as of today, August 12, 2025 only, and we'll include forward-looking statements and opinion statements including predictions, estimates, plans, expectations, and other similar information. Actual results may differ materially from those expressed or implied as a result of certain risks and uncertainties. These risks and uncertainties are more fully described in our press release issued earlier today and in our filings with the US Securities and Exchange Commission.
Our SEC filings can be found on our website or the SEC's website. Investors are cautioned not to place undue reliance on forward-looking statements. We
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
